65,437 trials
Healthy
Primary: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] — 291.3; 575.6; 1282.0; 1278.0 ng* hr/mL
Crohn's Disease
Primary: Occurrence of at Least One Study-emergent Adverse Event During the Study (Maximum 164 Weeks) — 92.6 percentage of participants
Cystoid Macular Edema
Primary: Central Macular Thickness (Difference in Mean Pre-post Changes by the Two Treatment Groups) — 2.78; 5.6 microns — p=0.7029
Thrombocytopenia
Primary: Change in Post-transfusion Platelet Counts — 99; 97.5 Platelets (*10^3/mm^3) — p=0.8
Diabetic Retinopathy
Primary: Change in Central Subfield Retinal Thickness From Baseline Over All Study Visits — 21; -35; -86; -3 microns — p=0.009
Jaw, Edentulous
Primary: Bone Level Change on Radiographs — 2.91; 2.11; 1.70 mm
Metabolic Syndrome · Insulin Resistance · Prediabetes
Primary: Change in Insulin Sensitivity Using FSIGT — 1.7; 2.4; 7.02 FSIGT units (x10^-4/min/uU/ml)
HIV Infections · HIV-1
Primary: Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <50 Copies Per mL) at Week 48 — 291; 276; 24; 18…
Pulmonary Heart Disease
Primary: Percent Change in Pulmonary Artery Pressure Change From 1 Minute Pre-dose to 31 - 35 Minutes Post Dose — -1.9; -1.7 mm Hg
Temporomandibular Joint Disorders
Primary: Characteristic Pain Intensity (Characteristic Intensity of Facial Pain) — 3.1; 2.9; 3.6 units on a scale — p=0.19
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Glycosylated Hemoglobin (Week 12). — -0.54; -0.64; 0.21 percentage of Glycosylated Hemoglobin
Hypersensitivity
Primary: The Percentage of Participants With Adjudicated Hypersensitivity Signs/Symptoms, for Each Sugammadex Dose Group and Placebo. — 0.7; 4.7; 0 percentage of participants
Influenza · Swine-origin A/H1N1 Influenza
Primary: Number of Participants With Antibody Titers ≥ 10 1/Dilution (1/Dil) Against A/California (H1N1 Vaccine) Strain - Age 6 to 35 Months — 5; 2; 0; 72 Participants
Lung Cancer
Primary: Number of Participants With Absence of Pneumothoraces — 18; 18 Participants
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Glycosylated Hemoglobin (Week 12). — 0.04; -0.96; -0.91 percentage of Glycosylated Hemoglobin